Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erbitux, Xeloda, and Eloxatin with or without Avastin in metastatic colorectal cancer
NCT00321100Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Apr 2006
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (CRC), sponsored by Fox Chase Cancer Center. Started Apr 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00321100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321100.